|
|
Home
Publications
Consultations
2000
Summary Report of the President/CEO Industry Hearing to CBAC
Ottawa, Ontario
September 29, 2000
Rapporteur’s Summary
By E. Richard Gold
Assistant Professor
Faculty of Law, University of Western Ontario
Senior Fellow
Einstein Institute for Science, Health & the Courts
Research Associate
Health Law Institute, University of Alberta
- The President/CEO Briefing to CBAC brought together representatives from the
pharmaceutical, biopharmaceutical, animal biotechnology, and plant biotechnology industries as
well as intellectual property lawyers and a social scientist to discuss industry needs with respect
to biotechnology patents. As the two Co-Chairs of the Briefing made clear, CBAC is interested
in examining ways in which to foster biotechnological innovation in a way that is both consistent
with Canadian values and contributes to the Canadian economy.
- Although the Briefing was organised to give an overview of industry needs in the area of
biotechnological innovation, it was not designed to solicit all views from all industry sectors.
While several industries were not in attendance at the Briefing--including genetic testing
companies, genetic therapy companies, producers of non-pharmaceutical bioproducts in the
health care area, and bio-informatics companies–those selected represented a cross-section of
the biotechnology industrial community.
- Industry participants did not address in any detail the social and ethical context in which
biotechnological research is or ought to be conducted in Canada, the respective roles of the
public and private sectors in conducting this research, the role of the Canadian public in setting
biotechnology policy, or the economic or social effects of patents either in general or in relation
to biotechnology. Several industry participants did state, however, that they supported public
research and some believed that industry-university research collaborations represented one
means that their companies used to assist public sector research. They also believed that the
biotechnology industry had salutary social effects such as increased employment opportunities in
Canada and the training of future management personnel.
- Ted Schrecker, the invited social scientist, pointed out that biotech patenting involved important
social and ethical questions. He warned that it was “cognitively irresponsible” for policy-makers
to look at life forms as equivalent to machines and cautioned against an overly technical
approach to formulating patent policy. He suggested that, before proceeding with biotech
patents, we first examine the economic effects that these patents have on health care and health
care costs. He also argued that CBAC should undertake a consultation on biotechnology
patents with university-based researchers at various stages of their scientific careers.
- The industry participants focussed their presentation on three main areas of concern. The first
involved the manner in which international investors and affiliates perceive the Canadian climate
for biotechnological research and development. The second involved the need for efficiency in
obtaining, using, and enforcing patent rights. The third area of concern related to particular
industry needs in the fields of pharmaceuticals-biopharmaceuticals, animal biotech, and plant
biotech.
Canada’s International Perception
- One of the strongest and most uniform messages that the industry representatives conveyed was
that Canada is viewed internationally as being unsupportive of, or even hostile to,
biotechnological innovation. This perception is based on a variety of Canadian policies of which
intellectual property protection is one. According to the industry representatives, those who
make decisions about investing in Canadian research view Canadian patent laws as being less
broad, more difficult to enforce, shorter, and longer to obtain than those in the United States,
Europe, and Japan. Canada also has the reputation of being unwilling to live up to its
international obligations with respect to patent protection.
- While industry representatives pointed to the fact that Canada does not meet current standards
set by the United States, Europe, and Japan with respect to patents, they acknowledged that,
given the small size of the Canadian marketplace, this fact has little economic significance. In
fact, Canada only accounts for approximately 2.5% of the worldwide pharmaceutical market.
Since patent protection is worldwide and is particularly valuable in the major world markets–in
particular in the United States and Europe–patent protection levels in Canada have little direct
economic effect on decisions as to where to conduct research and development. This is
because an invention developed in Canada can, despite Canadian patent laws, be patented and
exploited in the United States and in Europe on identical terms to inventions developed in those
regions.
- Despite the fact that the strength of Canadian patent rights lack any direct economic impact on
Canadian biotechnological research and development, Canadian industry is concerned about the
indirect message that failure to meet international patent standards has on foreign investors and
affiliates. This is because investors and affiliates often do not make decisions about where to
invest based solely on measurable economic factors. They also take into account less
quantifiable perceived innovation climates.
- The representatives from the Canadian branches of the international pharmaceutical industry
pointed out, for example, that it was difficult to convince their head offices to invest in research
and development in Canada because of the perception that Canada does not treat these
companies fairly in its patent policies. The Canadian representatives did not share the opinion
that Canada was unsupportive of biotechnological innovation. In fact, Canada’s publicly funded
health care system and universities make Canada, in some respects, an ideal place to conduct
research. Nevertheless, the negative perception that Canada is hostile to biotechnological
research prevents Canada from capitalizing on this advantage.
- Canadian-based industry had similar views about the attitudes of international biotechnology
investors contemplating investments in Canada. Industry representatives believed that these
investors would at least hesitate before investing in a Canadian biotechnology company because
of the view that Canada was unsupportive of biotechnological innovation as exemplified in its
patent policies.
- Because of the relatively small economic impact that the Canadian market has on investment
decisions, industry, other than the pharmaceutical companies, generally file their patents first in
the United States. This is so for a number of reasons. First, patent protection in the major
markets is required to attract investment. Venture capitalists and other investors care little about
a company’s patent position in Canada but care deeply about patent positions in the United
States and Europe. Second, the companies themselves are more interested in selling into the
United States’ market than the Canadian market because of the former’s size. Third, there has
been, up to now, greater secrecy governing patents in the United States than those filed
elsewhere. This will change in November 2000 when the United States will open patent
applications to public view 18 months after the earliest filing date or priority date of the
application unless the patent is being filed solely in the United States. The pharmaceutical
industry generally follows the rule that patents are first filed in the country in which the invention
takes place and, following that, internationally.
- In the past, when Canada increased its level of patent protection, industry increased its
investment in Canadian research and development. Industry representatives stated that
international pharmaceutical companies increased their research staffs significantly after changes
to Canada’s patent laws in 1987 and 1993. There has also been a two to threefold increase in
research and development in the agricultural biotechnology sector in Canada since 1996 but this
does not seem to be tied to any significant change in the scope of Canadian intellectual property
rights.
- Most industry representatives stated that there exists a robust investment climate in Canada with
an increasing number of sophisticated and knowledgeable venture capitalists. One industry
representative reported, however, that this robustness is not uniform. He stated that investors
tend to look for technologies that enter niche markets and are suspicious of technologies with
wide application. His company, which produced a product of broad application, had
encountered difficulty in finding investors.
Efficiency in the Administration of the patent System
- Industry representatives were uniform in calling for an easier to use and more transparent patent system in Canada. They voiced several concerns over the present administration of the
Canadian patent system. First, they stated that the review of patent applications in Canada is
too slow. Second, they pointed to the lack of patent term restoration periods as exists in the
United States, Europe, and Japan to compensate patent holders for regulatory delays in getting
an invention to market. Third, they noted particular areas where the Canadian patent system can
be made more efficient.
Patent Review Periods
- While industry representatives were happy with the quality of the Canadian Intellectual Property
Office’s (CIPO) review of their patent applications, they felt that the length of time that patent
applications sit unexamined in the patent office is unacceptable. It takes, on average, 22 months
after a request by an applicant for CIPO to formally respond to the application (the first office
action). Since most patent applications arriving in Canada come through the Patent Cooperation
Treaty (PCT)–an international convention that provides for a mechanism to file patent
applications in many countries at once–most applications will already have been in process for
approximately 30 months prior to this 22 month period. This means that the applicant does not
usually receive a first office action from CIPO before four years after the initial filing. While
industry representatives acknowledged that applicants may seek special orders to have their
applicants reviewed on a more urgent basis, they felt that this procedure is unfair to other
applicants who, as a result, have to wait longer for the review of their applications.
- Timeliness of patent application review would assist industry in several ways, according to the
representatives. First, it would make it easier to attract investors and business partners earlier in
the patent term. Since investors and potential partners are less interested in investing in
technology without a firm patent, delays in patent prosecution mean that an inventor will have to
wait longer before approaching these investors and partners. Nevertheless, since the 20 year
period of exclusivity continues to run during the patent prosecution period, the invention
becomes less valuable with every passing day. Thus, not only is production and distribution of
the invention delayed, but it may never take place if so much of the 20 year period has expired
that the patent no longer has sufficient value to justify an investment.
- To remedy this problem of patent review delays, industry representatives recommend active
recruitment of new patent examiners and increased training of those hired. In addition, they
recommend that CIPO rely more on patent examinations conducted in other countries,
particularly in the United States, so as to simplify the Canadian portion of the review.
Patent Term Restoration
- The pharmaceutical and biopharmaceutical industry representatives raised another concern
related to timeliness: regulatory delays in gaining approval to new medications. These industries,
as opposed to most biotechnology companies including most in the health care sector, require
regulatory approval by the Health Protection Branch of Health Canada before placing their
products on the Canadian market. They require similar regulatory approvals elsewhere (for
example, approval from the Federal Food and Drug Administration in the United States). On
average internationally, this approval takes between 10 and 12 years. Small biopharmaceutical
companies may find that it takes longer to get approval since they are, generally, less
experienced with the approval process. The end result of the need for health-related review is
that the effective life of a biopharmaceutical patent is only eight years as compared to closer to
17 years (assuming a three year delay in obtaining a patent) for other biotechnological and other
technology patents.
- In addition to the short effective lifespan of pharmaceutical patents, the cost of bringing these
products to market is much larger than for most inventions including most biotechnological
inventions. This again is because of regulatory review. In order to comply with the regulatory
review process, pharmaceutical and biopharmaceutical companies must conduct expensive trials
and tests. On average, it costs approximately U.S.$500,000 to bring one medication to market.
With only eight years to recoup these costs, the pharmaceutical and biopharmaceutical
industries feel that the Canadian patent system does not provide a fair return for their
investments.
- All of the United States, Europe, and Japan address the concern over regulatory delays in the
approval of medications by granting patent term extensions. Under these patent term restoration
rules, patent terms may be extended by the relevant patent office for up to five years. Canada
does not have similar rules. The pharmaceutical and biopharmaceutical industries believe that
Canada’s lack of patent term restoration rules contributes to the international perception that
Canada is unsupportive of biotechnological innovation.
Other Suggestions
- In addition to industry concerns over the timeliness of patent reviews and the request, in the
pharmaceutical and biopharmaceutical sectors, for patent term restoration rules, industry raised
a number of other issues related to the efficiency of the Canadian patent system.
- One area in which improvement is needed is in the clarity of the patent process. Industry
representatives pointed to the policy of the United States Patent and Trademark Office (PTO)
of making the procedures to file and obtain patents as clear and straightforward as possible. For
example, the PTO issues guidelines on filing applications and in assisting would-be applicants in
understanding such concepts as description and utility requirements. To date, CIPO has not
issued any guidelines of a similar nature.
- While industry participants did not address the issue of the respective roles of the public and
private sector in advancing biotechnological innovation, they acknowledged the need to
encourage university research and to bring the products of that research to market. They
pointed to the need for a more developed institutional infrastructure to patent university research
and to create university-industry partnerships to move the products of that research to market.
The industry representatives believed that industry has an important role in this area. In fact, one
of the representatives from the pharmaceutical industry pointed out that her company engaged in
partnerships with universities in order to further develop university research and research
capacity.
- Several of the participants pointed to the lack of any clear rules in Canada (or in the United
States) on the type of research that is permitted to be conducted using patented inventions
without infringing a patent holder’s rights. The so-called experimental use exception is ill-defined
in Canada and the United States as opposed to in Europe. This lack of clarity results in a grey
zone for researchers in which they face the risk of being sued for patent infringement.
- While the industry representatives agreed on the need to clarify the experimental use exception
in Canada, they did not agree on the appropriate scope of the exception. The pharmaceutical
and bio-pharmaceutical industries called for a narrow exception–one narrower, in fact, than
current practice in Canada, Europe, and the United States. By statute in the United States and
by judicial interpretation in Europe and Canada, rival companies are permitted to conduct
clinical trials on generic versions of a patented medication without infringing on the patent
holder’s rights. The pharmaceutical industry believes that this is unfair and that experimental use
ought to be limited to truly innovative research.
- Other industry representatives favoured a wider approach to the experimental use exception
probably closer to the European standard where any research conducted on the subject-matter
of a patent–even if the research is conducted for commercial purposes–is permitted. Some
patent analysts believe that this is also the de facto standard in the United States even though
there is no clear jurisprudence to this effect. A more generous research exception prevents any
one company from holding back future rounds of innovation.
- The agricultural industry is, in particular, concerned that patents not block access to platform
technologies. Although the industry’s preferred route to have access to this technology is
through licensing and cross-licensing arrangements, there is a perceived need to ensure that no
one company can block access to new germ plasm as it is developed.
- Industry representatives generally supported the ability to patent higher life forms–plants and
animals more complex than microorganisms. From a commercial point of view, they stated that
there was nothing different between higher life forms and existing patentable material. They
stated that Canada ought to harmonize its laws with those of the United States and Europe in
which higher life forms are patentable. This is necessary in order to further develop our expertise
in transgenic animals. Ted Schrecker pointed out, however, that there are vast moral and social
differences between property rights in higher life forms and those in other inventions.
- There was general consensus that the utility and description guidelines for biotechnological
innovation ought to be harmonized internationally. The proposed guidelines on these points
issued by the PTO in December 1999 found general favour among the industry representatives.
30. One of the lawyers invited to the Briefing stated that one of the ways that the United States had
achieved uniformity and clarity in its patent laws was through the formation of a specialized
court, the Federal Court of Appeals for the Federal Circuit, to deal with patent issues. He
suggested that Canada consider establishing a specialized patent court, perhaps within the
existing Federal Court of Canada structure.
- In addition to these general proposals, industry representatives strongly recommended that
Canada continue some of its current practices that are viewed as beneficial to the biotechnology
community. These include Patent Act provisions (s. 52) permitting an individual to challenge an
issued patent without having to first infringe on the patent. This is an advantage of the Canadian
patent system over that in the United States. Similarly, the introduction in 1996 of a procedure
(sections 93 and 94 of the Patent Rules SOR 96-423) under which applicants can file
“provisional” applications to protect a priority date over an invention was seen as positive. This
procedure matches the provisional patent application procedure in the United States.1
- On the other hand, industry viewed Canada as falling behind in conforming to international
standards on the filing of genetic sequences. One industry representative also suggested that
Canada implement a continuation practice procedure–under which patent applicants can revive
dormant patent applications–as in the United States. Another innovative proposal was that,
where some of the claims in a patent application were in dispute while others were not, that
CIPO issue a patent over the undisputed claims while the disputed claims continue through the
court system.
Particular Industry Concerns
- Although there was much uniformity in the views of the industry representatives, there were also
substantial differences. Each industry sector put forward suggestions as to changes that would,
in the opinion of the representatives, foster innovation in that sector.
Pharmaceutical and Biopharmaceutical Industries
- There was little difference in the positions of the pharmaceutical and biopharmaceutical
industries. This was due, in part, to the absence of any generic biopharmaceutical industry given
that regulations and bioequivalence standards have not yet been established for
biopharmaceuticals.
- The pharmaceutical industry is very concerned, according to their representatives, about the
protection of their research data. As discussed earlier, clinical trials are expensive to conduct.
The pharmaceutical industry wants to ensure that, when a company submits clinical trial data to
Health Canada, that this information remains confidential. In particular, companies do not want
their competitors or generic companies to have access to this information. Currently, the
industry feels that there is insufficient protection given to this information. The representatives
called for amendments to the Food and Drug Act to strengthen the confidentiality of submitted
research data.
- The industry has not encountered difficulties with confidentiality when sharing information with
university researchers. The industry representatives stated they they respect the need of
university researchers to publish their research findings. When pharmaceutical companies share
information with these researchers, they impose restrictions on the further dissemination of this
information but not the information produced by the researchers. They accomplish this by
incorporating a short delay period prior to publication so that the pharmaceutical company can
review the proposed publication. The company would only not agree to the publication of the
material if it contained confidential information supplied by the company or where one research
group in a muti-centre trial attempted to publish ahead of the other research teams.
- Where a pharmaceutical company has highly sensitive information, it generally will not share that
information with university researchers, preferring to either conduct the research in-house or to
contract the research out to the private sector under a strong confidentiality agreement. While
the effect of this practice may be to reduce university researchers’ access to some information, it
preserves the freedom to publish research results.
- The industry complained that Canada was reluctant to fully enforce pharmaceutical patents. This
is most clearly demonstrated, according to the representatives, in the so-called linkage
regulations that are, in principle, designed to restrict a generic company’s ability to gain approval
to market a medication until the patent over that medication expires. In fact, according to the
pharmaceutical industry, these linkage rules are not strong enough to prevent the generic
companies from getting a significant lead on the approval of generic medications during the life
of the patent.
- Industry representatives were supportive of an orphan drug law in Canada. Under such a law,
industry would receive certain benefits–including exclusivity in the market and tax incentives--to
develop and market medications that affect only a small number of individuals in Canada. This
legislation is needed to encourage research and development into ameliorating rare diseases.
While the pharmaceutical industry does, on occasion, investigate rare diseases, it normally only
does so where it can learn from that investigation knowledge of wider application. Orphan drug
laws would encourage others, particularly small biotechnology companies, to conduct research
on rare diseases.
Animal Biotechnology
- The largest problem facing the animal biotechnology sector is not related to intellectual property
protection: it is the lack of regulation. According to the industry representative from this sector,
there is a complete vacuum of regulation in the animal biotechnology area, for example, with
respect to environmental, animal care, and similar laws and regulations that apply to the care of,
disposition of, and waste produced by genetically-modified animals. Almost any regulation
would be better than the current absence of rules. As it stands, industry cannot assess its
liabilities and cannot engage in any long-term planning about genetically-modified animals since
no regulatory framework exists.
- Canada is significantly behind other countries in establishing its rules and regulations with respect
to genetically-modified animals. According to the industry representative, Canada is at least five
years behind the United States in this area.
Agricultural Biotechnology
- The international agricultural biotechnology industry relies on several different intellectual
property regimes ranging from patents, to trade secrets, to plant breeders rights. As in other
sectors, Canada’s policies with respect to agricultural biotechnology is viewed by industry as
being significantly behind those of the United States and Europe.
- Most developed nations permit inventors to choose between intellectual property regimes. That
is, a creator can select whether to protect a plant through a patent, plant breeders rights, or
trade secret. As Canada does not permit patent protection over plants, creators only have the
choice between trade secret protection and plant breeders rights. According to the industry
representative, this limited choice has negative implications for research in Canada as more and
more plant creators choose trade secret protection.
- Historically, plant developers openly shared their technologies. With the advent of genetic
engineering, which the industry feels is inadequately protected through plant breeders rights,
these developers have resorted to trade secret protection. Since, in order to maintain trade
secret protection, developers must maintain the secrecy of their inventions, they can no longer
maintain this open sharing of technology.
- The industry representative stated that if patents were available over plants, the plant developers
would resume their tradition of openness. This is because patented plants would be freely
disclosed through the patent process itself. Thus, developers could more easily share ideas
without fear of losing protection.
- Given that many of the developments in plant biotechnology tend to produce platform
technologies, it is extremely important that the tradition of sharing be maintained. Nevertheless,
since patent rights are so much broader than plant breeders rights, there remains a danger that a
particular plant developer will not conform to industry norms of openness. Patent law ought,
according to the industry representative, to contain mechanisms to prevent this hoarding of
technology. A broad experimental use exemption would help. Other options should also be
investigated.
- According to the industry representative, the best way for Canada to move forward in respect
of plant biotechnology is to re-introduce and pass former Bill C-90 (An Act to revise and
consolidate certain Acts respecting food, agricultural commodities, aquatic commodities and
agricultural inputs, to amend the Canadian Food Inspection Agency Act, the Agriculture and
Agri-Food Administrative Monetary Penalties Act, the Health of Animals Act, the Plant
Protection Act and the Plant Breeders' Rights Act, and to repeal and amend other Acts in
consequence). This Act would have the effect of harmonizing Canadian plant breeders rights
laws with those of the United States and Europe.
- Canada currently conforms to the 1978 UPOV Convention dealing with plant breeders rights.
Other developed nations have moved to the standards set out 1991 UPOV Convention which
not only permits patenting of plants, but enlarges the scope of plant breeders rights protection.
Bill C-90 was designed to move Canada to the 1991 UPOV Convention standard.
- Bill C-90 addressed important issues covered by the 1991 UPOV Convention. First, as already
stated, it permitted patenting of plants. Second, it defined what constitutes experimental use
within plant breeders rights. Third, it expanded protection by not only including plant varieties
themselves, but plants derived from those varieties (through the introduction of the concept of
essentially derived varieties) and material harvested from those plant varieties. The latter
protection is particular important in respect of ornamental plants and horticulture. Fourth, the bill
maintained the existence of farmers’ privilege under which a farmer could plant the seeds
harvested from a previous year’s crop. Fifth, the bill would have permitted a developer to gain
plant breeders rights protection even if a version of the plant had previously been sold in
Canada.
Conclusion
- The President/CEO Briefing to CBAC illustrated both the commonalities between the different
biotechnology industry sectors and some of the differences. While all pointed to the need to
rehabilitate the perception of the Canadian biotechnology climate held internationally and of the
need to make the Canadian patent system more efficient, the different industry sectors had
clearly different needs, some of which conflicted. The largest area of conflict surrounded which
types of use others could legitimately make of a patented invention without infringing on the
patent. In those industries where there is no tradition of sharing information, industry
representatives asked for narrow exceptions. In those industries with a greater tradition of
sharing, the representatives asked for wider exceptions.
1The industry representative who raised this point actually stated during the Briefing that Canada
ought to implement a procedure similar to the provisional patent application procedure in the United
States. As the 1996 amendments only affected patent applications made after October 1, 1996, this
representative may not have known that Canada had already done so.
|